{"id":1769,"date":"2022-03-17T15:32:51","date_gmt":"2022-03-17T15:32:51","guid":{"rendered":"http:\/\/localhost:10018\/?post_type=advocacy_newsletter&#038;p=1769"},"modified":"2022-09-29T15:38:03","modified_gmt":"2022-09-29T15:38:03","slug":"march-2022-advocacy-newsletter","status":"publish","type":"advocacy_newsletter","link":"https:\/\/cfacanada.org\/fr\/advocacy_newsletter\/march-2022-advocacy-newsletter\/","title":{"rendered":"March 2022 Advocacy Newsletter"},"content":{"rendered":"\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">    <div class=\"hero hero--without-image hero-banner-block alignfull\">\n        <div class=\"hero__wrapper container\">\n            <div class=\"row justify-content-between align-items-center g-0\">\n                <div class=\"d-flex col-12\">\n                    <div class=\"hero__content\">\n                        <h1 class=\"hero__title\">March 2022 Advocacy Newsletter<\/h1>\n                                                                                            <\/div>\n                <\/div>\n                            <\/div>\n        <\/div>\n    <\/div>\n\n\n\n\n\n<h2 class=\"wp-block-heading\">Download PDF:<\/h2>\n\n\n\n<p><a href=\"http:\/\/cfacanada.org\/wp-content\/uploads\/2022\/09\/Canadian-Advocacy-Newsletter_202203.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">March 2022 Advocacy Newsletter<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Summary:<\/h2>\n\n\n\n<p>The pace of requests for comment slowed during March, with the CAC submitting only one letter during the month. The members of the CAC responded to the CSA\u2019s notice on the proposed NI 93-101 and CP 93-101 relating to business conduct for OTC derivatives. This is the third consultation on NI 93-101 and CP 93-101, with the prior consultation having taken place in mid-2018. The changes from the prior iterations of the rule are intended to streamline the operationalization of the requirements (i.e. primarily to allow registered advisers to leverage their existing compliance infrastructure) and ensure that access to OTC products will not be unduly limited to customers in the Canadian OTC derivatives market. The CAC sees many of the provisions of the Proposed Instrument as improvements over the prior proposals and are responsive to comments and concerns raised by market participants, but is concerned with the time it\u2019s now taken to implement comprehensive OTC derivatives regulation in Canada, now being ~14 years since the GFC. The focus on maintaining liquidity for the Canadian marketplace is quite important given the structure of OTC derivatives markets and<\/p>\n<\/div>\n","protected":false},"featured_media":0,"template":"","categories":[],"class_list":["post-1769","advocacy_newsletter","type-advocacy_newsletter","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>March 2022 Advocacy Newsletter - CFA Societies Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"March 2022 Advocacy Newsletter - CFA Societies Canada\" \/>\n<meta property=\"og:description\" content=\"Download PDF: March 2022 Advocacy Newsletter Summary: The pace of requests for comment slowed during March, with the CAC submitting only one letter during the month. The members of the CAC responded to the CSA\u2019s notice on the proposed NI 93-101 and CP 93-101 relating to business conduct for OTC derivatives. This is the third [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/\" \/>\n<meta property=\"og:site_name\" content=\"CFA Societies Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-29T15:38:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cfacanada.org\\\/advocacy_newsletter\\\/march-2022-advocacy-newsletter\\\/\",\"url\":\"https:\\\/\\\/cfacanada.org\\\/advocacy_newsletter\\\/march-2022-advocacy-newsletter\\\/\",\"name\":\"March 2022 Advocacy Newsletter - CFA Societies Canada\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cfacanada.org\\\/#website\"},\"datePublished\":\"2022-03-17T15:32:51+00:00\",\"dateModified\":\"2022-09-29T15:38:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cfacanada.org\\\/advocacy_newsletter\\\/march-2022-advocacy-newsletter\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cfacanada.org\\\/advocacy_newsletter\\\/march-2022-advocacy-newsletter\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cfacanada.org\\\/advocacy_newsletter\\\/march-2022-advocacy-newsletter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cfacanada.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advocacy Newsletters\",\"item\":\"https:\\\/\\\/cfacanada.org\\\/fr\\\/advocacy_newsletter\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"March 2022 Advocacy Newsletter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cfacanada.org\\\/#website\",\"url\":\"https:\\\/\\\/cfacanada.org\\\/\",\"name\":\"CFA Societies Canada\",\"description\":\"Canadian investment values\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cfacanada.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"March 2022 Advocacy Newsletter - CFA Societies Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/","og_locale":"fr_FR","og_type":"article","og_title":"March 2022 Advocacy Newsletter - CFA Societies Canada","og_description":"Download PDF: March 2022 Advocacy Newsletter Summary: The pace of requests for comment slowed during March, with the CAC submitting only one letter during the month. The members of the CAC responded to the CSA\u2019s notice on the proposed NI 93-101 and CP 93-101 relating to business conduct for OTC derivatives. This is the third [&hellip;]","og_url":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/","og_site_name":"CFA Societies Canada","article_modified_time":"2022-09-29T15:38:03+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/","url":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/","name":"March 2022 Advocacy Newsletter - CFA Societies Canada","isPartOf":{"@id":"https:\/\/cfacanada.org\/#website"},"datePublished":"2022-03-17T15:32:51+00:00","dateModified":"2022-09-29T15:38:03+00:00","breadcrumb":{"@id":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cfacanada.org\/advocacy_newsletter\/march-2022-advocacy-newsletter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cfacanada.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Advocacy Newsletters","item":"https:\/\/cfacanada.org\/fr\/advocacy_newsletter\/"},{"@type":"ListItem","position":3,"name":"March 2022 Advocacy Newsletter"}]},{"@type":"WebSite","@id":"https:\/\/cfacanada.org\/#website","url":"https:\/\/cfacanada.org\/","name":"CFA Societies Canada","description":"Canadian investment values","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cfacanada.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cfacanada.org\/fr\/wp-json\/wp\/v2\/advocacy_newsletter\/1769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cfacanada.org\/fr\/wp-json\/wp\/v2\/advocacy_newsletter"}],"about":[{"href":"https:\/\/cfacanada.org\/fr\/wp-json\/wp\/v2\/types\/advocacy_newsletter"}],"wp:attachment":[{"href":"https:\/\/cfacanada.org\/fr\/wp-json\/wp\/v2\/media?parent=1769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cfacanada.org\/fr\/wp-json\/wp\/v2\/categories?post=1769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}